SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp rebound is being linked by traders to Morgan Stanley naming it a top pick on AWS growth and AI prospects, as well as AWS making its Trainium chips easier for developers to use. Bulls welcome the move and point to cloud and AI momentum, while skeptics question whether it can hold amid heavy capex and recent volatility.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, strengthening the case for an FDA resubmission, though approval remains ahead and dizziness incidence has drawn some concern. Traders are broadly bullish on the trial result, with discussion also focused on short-covering and whether the rally can hold.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are drawing attention after a sharp selloff and break below technical support, with traders pointing to disclosed insider selling and a DBS downgrade as possible pressures. The community is divided between expecting further declines and viewing the pullback as a buying opportunity, while some also cite weakness in Indonesian markets and broader regional macro concerns.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-expected third quarter and an upbeat 2027 EBITDA outlook are driving CLFs rally, with bullish traders anticipating short covering. Others warn the outlook depends on steel prices and remain focused on the companys debt, while some see the move as a sell-the-news bounce.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios FDA expansion of Anktiva plus BCG to papillary-only bladder cancer, alongside positive long-term trial data, is the main focus. The share-price decline despite those developments has prompted debate over profit-taking, broader biotech weakness and options activity, while some traders allege manipulation without substantiation.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicors raised Q3 growth outlook, driven by royalties from its Vertical Power Delivery licensing, is fueling positioning ahead of its earnings report. Traders are split between viewing the pullback despite stronger guidance and AI-power demand as an opportunity and worrying that volatility and high expectations could leave room for further weakness.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders citing insider share sales and upcoming lockup releases as added supply pressure alongside concerns about valuation, growth and its OpenAI exposure. Bears warn of further downside, while bulls argue the decline is overdone and are buying the dip; some also attribute weakness to a broader AI and semiconductor-sector retreat.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reported takeover interest from Lundbeck is driving speculation about a potential bid or bidding war and heightened trading activity. Xeris has said it is not for sale, leaving traders divided between treating the chatter as a credible deal catalyst and focusing on Recorlev growth and XP-8121s pipeline prospects.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is drawing attention amid a persistent selloff and weak solar-sector sentiment, with traders pointing to interest-rate sensitivity, policy and financing concerns, and analyst target cuts. The debate is whether its AI data-center, battery-storage and virtual-power-plant initiativesand perceived high short interestcould offset those pressures; some traders view them as a potential turnaround catalyst, while others remain bearish.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is drawing attention around its MSToronto multiple-sclerosis presentations, especially initial Phase 1 azer-cel findings in progressive MS and additional BRIUMVI data. Traders are hopeful the readouts and coming BRIUMVI milestones could support growth, while others are frustrated by choppy trading; buyout talk remains speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dollar at 3-Month Lows on Treasury Buyback Plans: ETF Strategies to Play

A weaker dollar and rising Treasury yields could create opportunities across inverse-dollar, gold, commodity, emerging-market and large-cap ETFs.

U.S. Dollar to Slip Ahead? ETFs in Focus 

The U.S. dollar could face downside risks as cooling inflation and softer jobs data reduce Fed rate-hike bets. Here are ETF strategies to follow.

What Lies Ahead for the U.S. Dollar? ETFs to Play Greenback's Outlook

The dollar could stay strong through year-end, but policy uncertainty and shifting sentiment may fuel a longer-term slide. Explore ETFs to position for both scenarios.

Japan and U.S. Join Hands to Support the Yen: ETFs to Benefit 

Japan and the U.S. step in to support the yen. See which ETFs could benefit from a stronger yen -- and which export-focused funds may face pressure.

The Zacks Analyst Blog Highlights UUP, USDU, UDN and CEW

UUP and other currency ETFs are in focus as a stronger U.S. dollar outlook meets longer-term diversification trends that could reshape global reserve allocations.

What Lies Ahead for the U.S. Dollar? ETFs That Investors May Consider

The dollar remains supported by a hawkish Fed, but structural shifts could reshape its long-term outlook. Explore ETFs to position for both scenarios.

Fading Haven Demand Hits Dollar: ETFs to Consider Now

As risk appetite returns, the greenback is losing its safe-haven shine. Let's take a look at ETFs that could benefit from a weakening USD.

Dollar Slides to Near Four-Year Low: ETF Strategies to Play

The U.S. dollar sinks to a near four-year low as yen strength, policy uncertainty and de-dollarization fuel interest in ETFs like UDN, FXY and GLD.

Dollar at a 4-Year Low? ETFs That You Could Play

The U.S. dollar sinks to a four-year low as rate-cut bets and policy uncertainty rise. These ETFs offer investors a way to hedge, diversify and capitalize on opportunities

ETFs That Investors May Consider Amid a Dollar Drag

As the dollar weakens and rate-cut bets rise, these ETFs offer investors a way to hedge, diversify and capitalize on opportunities.

Invesco DB US Dollar Index Bearish Fund - Invesco DB US Dollar Index Bearish Fund -1x Shares

Economist Steve Hanke Warns Faith In Dollar Is Eroding, Blames It On Trump’s Weaponization Of The Greenback

Equity

Bearish Sentiment

Economist Steve Hanke on Friday warned that faith in the U.S. dollar is eroding because of President Donald Trump’s economic policies and weaponization of the greenback.Hanke issued the warning in a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/steve_hanke/status/1953864785881125218">post</a> on X, citing the findings of Bank of America’s Global Fund Manager survey, which showed that fund managers are the most bearish on the U.S. dollar in 20 years.“TRUMP'S ECON POLICY = REGIME UNCERTAINTY,” Hanke warned in his post.<figure class="image"><img style="aspect-ratio:584/734;" src="https://news.stocktwits-cdn.com/Steve_Hanke_post_jpg_645df9f3c5.webp" alt="Steve Hanke's post on X" width="584" height="734"><figcaption>Steve Hanke's post on X | @steve_hanke/X</figcaption></figure>Hanke’s caution comes at a time when the dollar has been on a downward trajectory in 2025. The U.S. Dollar Index, which measures the greenback against a basket of currencies of the United States’ major trading partners, is down 10% year-to-date.Analysts at Morgan Stanley&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.morganstanley.com/insights/articles/us-dollar-declines">observed</a> that this is the biggest decline in the U.S. dollar in the last 50 years, bringing an end to its 15-year bull cycle. They expect the greenback to decline another 10% by the end of 2026.“The second act for the dollar’s weakening should come over the next 12 months, as U.S. interest rates and growth converge with those of the rest of the world,” said David Adams, head of G10 FX Strategy at Morgan Stanley.Analysts at JPMorgan&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://privatebank.jpmorgan.com/eur/en/insights/markets-and-investing/is-this-the-downfall-of-the-us-dollar">said</a> the dollar has now demonstrated its safe-haven status in 2025, with the greenback declining on the same days as U.S. stocks have closed in the red. This brings the “confidence premium” of U.S. assets into question, the firm noted, adding that President Trump’s tariff threats and his public challenges to the Federal Reserve and its chair, Jerome Powell, are leading to trust concerns.The&nbsp;<a href="https://stocktwits.com/symbol/USDU">WisdomTree Bloomberg U.S. Dollar Bullish Fund</a> (USDU) has declined over 5% year-to-date (YTD). The&nbsp;<a href="https://stocktwits.com/symbol/UUP">Invesco DB US Dollar Index Bullish Fund</a> (UUP) has declined 7% YTD, while the&nbsp;<a href="https://stocktwits.com/symbol/UDN">Invesco DB US Dollar Index Bearish Fund</a> (UDN) has surged nearly 12%.Stocktwits data showed the investor sentiment around the three ETFs was in the ‘neutral’ territory.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stocks-making-the-biggest-moves-today-august-8/chrnjNGRd4a">Trade Desk, SoundHound, Firefly, BitMine, Freddie Mac: Stocks Making The Biggest Moves Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, several $1 bills are seen displayed showing their front sides. 

Hanke cited the findings of Bank of America’s Global Fund Manager survey, which showed that fund managers are the most bearish on the U.S. dollar in 20 years.

US Dollar Index

Invesco DB US Dollar Index Bearish Fund

WisdomTree Trust - WisdomTree Bloomberg U.S. Dollar Bullish Fund

Invesco DB US Dollar Index Bullish Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$17.82
Prev Close	$17.86
Open	$17.83
Dividend Yield	N/A
50-Day Moving Average	$18.08
Beta	N/A
Avg. Volume	69,515.85
PE Ratio	N/A

52-Week High	$18.85
52-Week Low	$17.64
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

UDN Fundamentals